DCLK3 Antibody

What is DCLK3 and why is it significant for neuroscience research?

DCLK3 (Doublecortin-like kinase 3) is a neuronal kinase preferentially expressed in the striatum and dentate gyrus of the brain. Unlike its family members DCLK1 and DCLK2, DCLK3 shows a more neuron-specific pattern of expression. Its significance has been highlighted in multiple contexts:

• Expression is markedly reduced in Huntington's disease

• Plays a neuroprotective role against mutant huntingtin toxicity

• Regulates expression of genes involved in transcription regulation and chromatin remodeling

• Associated with anxiety-like behavior and cognitive functions

• Variants are risk factors for psychiatric disorders and brain alterations linked to age-related mild cognitive impairment

DCLK3 is distinct from other family members (DCLK1/2) in its structure, as it lacks the putative DCX domain in the N-terminal part present in DCLK1/2, with only 54-56% amino acid sequence identity .

What applications are DCLK3 antibodies validated for?

DCLK3 antibodies have been validated for multiple applications across various research contexts:

For optimal results, antibody dilutions should be determined empirically for each application, with recommended starting dilutions often provided by manufacturers (e.g., 1:5000-1:10000 for IHC) .

How can I validate the specificity of my DCLK3 antibody?

Validating antibody specificity is critical for reliable results. For DCLK3 antibodies, consider these methodological approaches:

• Positive and negative controls:

  • Use tissues with known high expression (striatum, dentate gyrus)

  • Include liver and kidney samples, which express DCLK3 but not DCLK1/2

  • Use DCLK3 knockout tissue as negative controls when available

• Molecular weight verification:

  • Confirm the ~73-74 kDa expected band in Western blots

  • Be aware of possible isoforms (long and short forms have been documented)

• Knockdown/knockout validation:

  • Compare with tissues/cells where DCLK3 has been silenced via shRNA

  • Use DCLK3 knockout mouse models as described in recent literature

• Peptide competition:

  • Block with the immunizing peptide to confirm signal specificity

  • Some antibodies were raised against synthetic peptides near N-terminus

• Cross-reactivity assessment:

  • Test across multiple species where appropriate (human, mouse, rat, monkey)

  • Check for cross-reactivity with other DCLK family members

What is the difference between different forms of DCLK3?

Research has identified multiple forms of DCLK3 with distinct characteristics:

• Long form (L-rDCLK3-HA):

  • Full-length protein with both N-terminal and C-terminal domains

  • Contains the complete kinase domain in the C-terminal region

  • Used in overexpression studies showing neuroprotective effects

• Short form (S-rDCLK3-HA):

  • Truncated version with altered structure compared to the long form

  • Has been cloned and used in experimental models

• Kinase domain only (Kin-rDCLK3):

  • C-terminal domain from amino acid 330 to the C-terminal end

  • Contains the active kinase domain responsible for neuroprotective effects

  • Used in studies to demonstrate the importance of kinase activity

When selecting antibodies, consider which form/domain you need to detect based on your research questions.

How can I use DCLK3 antibodies to study its role in Huntington's disease models?

DCLK3 has demonstrated significant relevance in Huntington's disease research. Here are methodological approaches using DCLK3 antibodies:

• Expression studies:

  • Use Western blotting to quantify DCLK3 levels in HD patient samples vs. controls

  • Compare DCLK3 expression in different brain regions (particularly striatum)

  • Track expression changes throughout disease progression

• Animal model studies:

  • Utilize IHC to visualize DCLK3 expression in mouse models (e.g., KI140CAG mice)

  • Combine with behavioral assessments (rotarod test, CatWalk, grip strength)

  • Compare DCLK3 levels with neurodegeneration markers

• Neuroprotection mechanisms:

  • Use IF/ICC to study subcellular localization before/after mutant huntingtin expression

  • Combine with markers for transcription regulation and chromatin remodeling

  • Perform co-immunoprecipitation to identify protein interactions in disease context

• Therapeutic targeting studies:

  • Monitor DCLK3 levels after experimental therapeutic interventions

  • Use viral vectors (AAV/lentiviral) to modulate DCLK3 expression

  • Perform chromatin immunoprecipitation (ChIP) assays to assess transcriptional impact

Recent research demonstrated that DCLK3 silencing exacerbated mutant huntingtin toxicity, while overexpression reduced neurodegeneration, indicating its potential as a therapeutic target .

What experimental approaches are most effective for studying DCLK3's role in transcriptional regulation?

DCLK3 has been identified as an important regulator of transcription and chromatin remodeling. Consider these methodological approaches:

• Chromatin association studies:

  • Use nuclear fractionation with DCLK3 antibodies to confirm nuclear localization

  • Perform ChIP-seq to identify genomic binding regions

  • Combine with histone modification markers to associate with chromatin states

• Protein interaction networks:

  • Immunoprecipitation with DCLK3 antibodies to identify binding partners

  • Focus on interactions with zinc finger proteins and TADA3 (a core component of SAGA complex)

  • Validate interactions with proximity ligation assays

• Transcriptomic analysis:

  • Compare gene expression profiles after DCLK3 modulation (knockdown/overexpression)

  • Focus on genes involved in transcription regulation and nucleosome/chromatin remodeling

  • In DCLK3 knockout models, examine expression of immediate early genes (e.g., Egr1, Fos, Per1, Nr4r1) and GABAA receptor subunits

• Functional domain studies:

  • Compare transcriptional effects of full-length vs. kinase domain-only DCLK3

  • Use kinase-dead mutants to determine kinase-dependency of transcriptional effects

  • Assess impact on polycomb-repressive complexes (PRC) activity

These approaches can help elucidate how DCLK3 functions in transcriptional regulation and chromatin remodeling pathways in neurons.

How can I distinguish between DCLK3 and other DCLK family members in my experiments?

Distinguishing between DCLK family members is crucial for accurate interpretation of results:

• Antibody selection strategies:

  • Choose antibodies raised against N-terminal regions where sequence divergence is greatest

  • DCLK3 lacks the DCX domain found in DCLK1/2, making this a potential differential target

  • Verify antibody specificity against recombinant DCLK1, DCLK2, and DCLK3 proteins

• Expression pattern analysis:

  • DCLK3 shows a more neuron-specific pattern compared to DCLK1/2 which are also expressed in astrocytes

  • DCLK3 transcripts are uniquely present in liver and kidney, where DCLK1/2 are absent

  • DCLK3 is mainly expressed in adult brain, not developing forebrain (unlike DCLK1/2)

• Molecular approaches:

  • Design PCR primers targeting unique regions of each family member

  • Use siRNA/shRNA with carefully validated specificity

  • When using overexpression systems, sequence verify constructs to confirm identity

• Knockout/knockdown controls:

  • Use tissue from DCLK3 knockout mice to validate antibody specificity

  • Consider genetic compensation effects (DCLK1 expression increases when DCX is disrupted)

Understanding the distinct roles of DCLK family members is important, as demonstrated by the severe phenotype observed in DCX/DCLK1 double mutants, which includes perinatal lethality and profound brain disorganization .

What methodological considerations are important when studying DCLK3's potential role in anxiety and memory functions?

Recent research has linked DCLK3 to anxiety-like behavior and spatial memory deficits. Consider these approaches:

• Animal model selection:

  • Use constitutive Dclk3 knockout mice for general behavioral phenotyping

  • Consider brain-region specific conditional knockouts (e.g., dorsal hippocampus) for targeted studies

  • Use viral-mediated loco-regional knockout approaches for temporal control

• Behavioral assessment battery:

  • Anxiety tests: elevated plus maze, open field test, light/dark box

  • Memory tests: spatial memory paradigms, particularly for hippocampal-dependent memory

  • Motor assessments to distinguish anxiety from motor deficits (rotarod, grip strength)

• Molecular and cellular characterization:

  • Analyze transcriptomic changes after DCLK3 knockout, focusing on:

    • GABAA receptor subunit expression (α2, β1, β2)

    • Immediate early genes (Egr1, Fos, Per1, Nr4r1)

    • Transcriptional regulators, particularly polycomb-repressive complexes

  • Perform metabolomic analysis to identify altered brain metabolites

• Immunohistochemical analysis:

  • Examine neuroanatomical alterations using DCLK3 antibodies

  • Assess expression of DCLK3 in anxiety-related brain circuits

  • Look for changes in synaptic plasticity markers

A recent study found that constitutive pan-deletion of Dclk3 is associated with anxiety phenotype in male mice, with changes in brain metabolites but without major neuroanatomical alterations. Additionally, dorsal hippocampus-specific knockout led to spatial memory deficits and specific transcriptomic changes .

How do mutations in DCLK3 impact its detection by antibodies and its function in disease models?

Understanding the impact of mutations on DCLK3 detection and function is critical for disease research:

• Epitope considerations:

  • Map the epitope recognized by your antibody relative to known mutation sites

  • Many commercial antibodies target N-terminal regions (amino acids near position 14-50)

  • For C-terminal kinase domain studies, select antibodies specifically targeting this region

• Functional domain mutations:

  • Kinase-dead mutations can help determine kinase-dependency of DCLK3 functions

  • Research has shown the kinase activity plays a key role in neuroprotection

  • Consider antibodies that can distinguish between active/inactive kinase conformations

• Disease-relevant variations:

  • The non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction

  • This variant has been linked to colorectal cancer progression

  • Design experiments to detect variation in expression levels rather than protein structure

• Experimental controls:

  • Include wild-type DCLK3 alongside mutated versions

  • Use recombinant proteins with specific mutations as antibody validation controls

  • Consider the impact of post-translational modifications on antibody binding

When studying DCLK3's role in disease, the relationship between genetic variations and protein function/detection is complex. For instance, the A-allele of rs1800734 within the promoter region of MLH1 perturbs binding of TFAP4, consequently increasing DCLK3 expression through long-range interaction, which promotes cancer malignancy by enhancing expression of epithelial-to-mesenchymal transition genes .

What are common pitfalls when working with DCLK3 antibodies and how can I overcome them?

Researchers may encounter several challenges when working with DCLK3 antibodies:

• Nonspecific binding:

  • Problem: Multiple bands in Western blots or nonspecific staining in IHC/IF

  • Solution: Optimize blocking (5% BSA or milk), increase antibody dilution (1:5000-1:10000) , use highly purified antibody preparations

• Epitope masking:

  • Problem: False negatives due to epitope inaccessibility

  • Solution: Test different antigen retrieval methods for formalin-fixed tissues, use multiple antibodies targeting different epitopes

• Isoform detection variability:

  • Problem: Inconsistent detection of different DCLK3 forms (long vs. short)

  • Solution: Select antibodies validated for your isoform of interest, use isoform-specific PCR primers as complementary approach

• Species cross-reactivity issues:

  • Problem: Antibody doesn't work across species despite sequence homology

  • Solution: Verify species reactivity (human, mouse, rat, monkey) , use species-specific antibodies when needed

• Low signal strength:

  • Problem: Weak detection of endogenous DCLK3

  • Solution: Use signal amplification methods, consider tissues with higher expression (striatum, dentate gyrus) , optimize fixation protocols

For optimal results, store antibodies according to manufacturer recommendations (typically 4°C for short-term and -20°C for long-term storage), and avoid repeated freeze-thaw cycles .

What is the most effective protocol for immunohistochemical detection of DCLK3 in brain tissue?

Based on published research, here's an optimized protocol for DCLK3 detection in brain tissue:

• Tissue preparation:

  • For formalin-fixed paraffin-embedded (FFPE) samples:

    • Fix tissue in 4% paraformaldehyde (PFA)

    • Process and embed in paraffin

    • Section at 40-μm thickness for good morphological preservation

• Antigen retrieval (critical for FFPE tissues):

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Bring to boil and maintain at 95-98°C for 20 minutes

  • Cool gradually to room temperature

• Blocking and permeabilization:

  • Block with 5-10% normal serum (from species of secondary antibody)

  • Add 0.1-0.3% Triton X-100 for improved antibody penetration

  • Include 1% BSA to reduce background

• Primary antibody incubation:

  • Dilute DCLK3 antibody 1:5000-1:10000 in blocking buffer

  • Incubate overnight at 4°C

  • For co-labeling, combine with antibodies against neuronal markers or other proteins of interest

• Detection system:

  • For chromogenic detection: Use appropriate HRP-conjugated secondary antibody and DAB substrate

  • For fluorescence: Use fluorophore-conjugated secondary antibodies matching your microscopy setup

  • Consider tyramide signal amplification for low abundance targets

• Controls:

  • Include positive control (striatum/dentate gyrus)

  • Include negative control (omit primary antibody)

  • When available, use DCLK3 knockout tissue as specificity control

This protocol has been successfully used to demonstrate DCLK3 localization in the nucleus of striatal neurons, supporting its role in transcription regulation and chromatin remodeling .

How can I design experiments to study the interaction between DCLK3 and its binding partners?

To effectively study DCLK3 protein interactions:

• Co-immunoprecipitation approaches:

  • Use DCLK3 antibodies to pull down native protein complexes

  • Focus on interactions with zinc finger proteins and TADA3 (part of SAGA complex)

  • Verify interactions by reverse co-IP with antibodies against suspected binding partners

• Proximity-based methods:

  • Proximity ligation assay (PLA) to visualize protein interactions in situ

  • BioID or APEX2 proximity labeling with DCLK3 as bait

  • FRET/BRET approaches with fluorescently tagged proteins

• Domain mapping strategies:

  • Create constructs expressing different DCLK3 domains (especially the kinase domain)

  • Use truncation mutants to map interaction interfaces

  • Compare wild-type and kinase-dead mutants to determine kinase-dependency

• Functional validation:

  • Assess the impact of disrupting interactions on:

    • Transcriptional regulation

    • Chromatin remodeling

    • Neuroprotective effects against mutant huntingtin

• Data analysis considerations:

  • Use appropriate controls to filter out false positives

  • Validate key interactions across multiple methods

  • Perform bioinformatic analysis of interaction networks

Research has shown that the kinase domain of DCLK3 interacts with zinc finger proteins, including TADA3, linking DCLK3 to histone acetylation and transcription machinery through the SAGA complex .

How can DCLK3 antibodies be utilized to understand its dual role in neurodegeneration and oncology?

DCLK3 has emerging roles in both neurodegeneration and cancer, offering interesting research opportunities:

• Comparative expression analysis:

  • Use DCLK3 antibodies to analyze expression in:

    • Normal brain tissue vs. neurodegenerative disease samples

    • Normal epithelium vs. colorectal cancer tissue

    • Various cancer types where DCLK3 expression may be altered

• Mechanistic investigations:

  • Study DCLK3's anti-apoptotic effects in neurons and cancer cells

  • Examine how DCLK3 regulates epithelial-to-mesenchymal transition in cancer

  • Compare transcriptional targets in neuronal vs. cancer contexts

• Genetic variant impact:

  • Investigate how the non-coding variant rs1800734 affects DCLK3 expression in different tissues

  • Study long-range chromatin interactions mediated by DCLK3

  • Analyze how DCLK3 variants affect disease progression in both contexts

• Therapeutic potential assessment:

  • Evaluate DCLK3 as a neuroprotective agent in neurodegenerative diseases

  • Explore DCLK3 inhibition as a potential cancer therapy

  • Develop tissue-specific targeting strategies

Research has shown that DCLK3 can have protective effects in Huntington's disease models , while increased expression due to the rs1800734 variant is associated with colorectal cancer malignancy , highlighting its context-dependent roles.

What are promising research directions for using DCLK3 antibodies in psychiatric and cognitive disorder studies?

Recent findings linking DCLK3 to psychiatric disorders and cognitive functions open several research avenues:

• Clinical correlation studies:

  • Use DCLK3 antibodies to analyze expression patterns in:

    • Post-mortem brain samples from psychiatric disorder patients

    • Animal models of anxiety, depression, and cognitive disorders

    • Development and aging brain tissues

• Circuit-specific analyses:

  • Combine DCLK3 immunostaining with circuit tracing methods

  • Focus on anxiety circuits and hippocampal memory pathways

  • Analyze DCLK3 expression in specific neuronal subtypes

• Synaptic plasticity investigations:

  • Study DCLK3's involvement in synaptic plasticity mechanisms

  • Analyze GABAA receptor subunit expression and function

  • Examine immediate early gene regulation by DCLK3

• Therapeutic target development:

  • Screen compounds that modulate DCLK3 expression or activity

  • Test effects on anxiety-like behaviors and memory formation

  • Develop targeted approaches based on DCLK3's role in specific brain regions

Recent research demonstrated that Dclk3 knockout led to anxiety phenotypes in male mice and spatial memory deficits when deleted in the dorsal hippocampus, along with specific transcriptomic changes involving GABAA receptor subunits and immediate early genes .

What experimental approaches combine DCLK3 antibodies with other technologies for comprehensive functional insights?

Integrating multiple technologies with DCLK3 antibody-based methods can provide deeper insights:

• Multi-omics approaches:

  • Combine ChIP-seq using DCLK3 antibodies with RNA-seq after DCLK3 modulation

  • Integrate proteomics data from DCLK3 immunoprecipitation with transcriptomics

  • Add metabolomics data to understand downstream effects of DCLK3 activity

• Advanced imaging methods:

  • Super-resolution microscopy to visualize DCLK3 subcellular localization

  • Live-cell imaging with tagged DCLK3 to track dynamic processes

  • Expansion microscopy for detailed nuclear localization studies

• CRISPR-based technologies:

  • CUT&RUN or CUT&Tag with DCLK3 antibodies for precise chromatin binding profiling

  • CRISPR activation/inhibition of DCLK3 combined with antibody-based detection

  • CRISPR screens to identify genes that modify DCLK3 expression or function

• Single-cell approaches:

  • Single-cell immunostaining for DCLK3 in brain tissue

  • Combine with single-cell transcriptomics to correlate expression patterns

  • Spatial transcriptomics paired with DCLK3 protein detection

• In vivo functional analysis:

  • Fiber photometry or miniscope imaging in DCLK3 reporter animals

  • Optogenetic or chemogenetic manipulation of DCLK3-expressing neurons

  • In vivo CRISPR editing followed by antibody-based validation